-
Product Insights
NewPulmonary Arterial Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Arterial Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea, and other diseases, including congenital heart disease,...
-
Product Insights
NewChronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Chronic Thromboembolic Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Chronic thromboembolic pulmonary hypertension (CTEPH) also called as Chronic pulmonary embolism, is a pulmonary vascular disease caused by chronic block of the major lung arteries. It is the major cause of chronic PH leading to right heart failure and death. The Chronic Thromboembolic Pulmonary Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewPulmonary Hypertension – Drugs In Development, 2024
Empower your strategies with our Pulmonary Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary hypertension (PH) is a rare condition marked by high blood pressure in the pulmonary arteries, which supply blood to the lungs. It can stem from various causes, including heart or lung diseases. PH leads to arterial narrowing, forcing the heart to work harder, potentially resulting in heart failure. Common symptoms include breathlessness, fatigue, chest pain, and dizziness. Management involves medication, oxygen...
-
Sector Analysis
Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Pulmonary Arterial Hypertension Market Overview The Pulmonary Arterial Hypertension (PAH) market size across the 7MM was valued at $4.6 billion in 2019 and is forecast to grow at a CAGR of more than 4% during 2019-2029. Pulmonary Arterial Hypertension Market Outlook To gain more information on the Pulmonary Arterial Hypertension market forecast, download a free report sample The Pulmonary Arterial Hypertension market research report provides an overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Market Size (2019)...